REGN
Price
$579.61
Change
-$7.35 (-1.25%)
Updated
Aug 28 closing price
Capitalization
61.43B
62 days until earnings call
SMMT
Price
$24.42
Change
-$0.39 (-1.57%)
Updated
Aug 28 closing price
Capitalization
18.14B
68 days until earnings call
Interact to see
Advertisement

REGN vs SMMT

Header iconREGN vs SMMT Comparison
Open Charts REGN vs SMMTBanner chart's image
Regeneron Pharmaceuticals
Price$579.61
Change-$7.35 (-1.25%)
Volume$616.62K
Capitalization61.43B
Summit Therapeutics
Price$24.42
Change-$0.39 (-1.57%)
Volume$2.73M
Capitalization18.14B
REGN vs SMMT Comparison Chart in %
Loading...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
REGN vs. SMMT commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Buy and SMMT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (REGN: $579.61 vs. SMMT: $24.42)
Brand notoriety: REGN: Notable vs. SMMT: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REGN: 67% vs. SMMT: 80%
Market capitalization -- REGN: $61.43B vs. SMMT: $18.14B
REGN [@Biotechnology] is valued at $61.43B. SMMT’s [@Biotechnology] market capitalization is $18.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REGN’s FA Score shows that 1 FA rating(s) are green whileSMMT’s FA Score has 0 green FA rating(s).

  • REGN’s FA Score: 1 green, 4 red.
  • SMMT’s FA Score: 0 green, 5 red.
According to our system of comparison, SMMT is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REGN’s TA Score shows that 4 TA indicator(s) are bullish while SMMT’s TA Score has 3 bullish TA indicator(s).

  • REGN’s TA Score: 4 bullish, 4 bearish.
  • SMMT’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, REGN is a better buy in the short-term than SMMT.

Price Growth

REGN (@Biotechnology) experienced а -3.10% price change this week, while SMMT (@Biotechnology) price change was -6.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.14%. For the same industry, the average monthly price growth was +15.09%, and the average quarterly price growth was +29.14%.

Reported Earning Dates

REGN is expected to report earnings on Oct 30, 2025.

SMMT is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (-1.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($61.4B) has a higher market cap than SMMT($18.1B). SMMT has higher P/E ratio than REGN: SMMT (26.36) vs REGN (14.61). SMMT YTD gains are higher at: 36.845 vs. REGN (-18.283). REGN has higher annual earnings (EBITDA): 5.42B vs. SMMT (-743.48M). SMMT has less debt than REGN: SMMT (5.55M) vs REGN (2.71B). REGN has higher revenues than SMMT: REGN (14.2B) vs SMMT (0).
REGNSMMTREGN / SMMT
Capitalization61.4B18.1B339%
EBITDA5.42B-743.48M-729%
Gain YTD-18.28336.845-50%
P/E Ratio14.6126.3655%
Revenue14.2B0-
Total CashN/A298M-
Total Debt2.71B5.55M48,712%
FUNDAMENTALS RATINGS
REGN vs SMMT: Fundamental Ratings
REGN
SMMT
OUTLOOK RATING
1..100
699
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
95
Overvalued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6349
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for SMMT (95). This means that REGN’s stock grew significantly faster than SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (42) in the Biotechnology industry is somewhat better than the same rating for REGN (100). This means that SMMT’s stock grew somewhat faster than REGN’s over the last 12 months.

SMMT's SMR Rating (100) in the Biotechnology industry is in the same range as REGN (100). This means that SMMT’s stock grew similarly to REGN’s over the last 12 months.

SMMT's Price Growth Rating (49) in the Biotechnology industry is in the same range as REGN (63). This means that SMMT’s stock grew similarly to REGN’s over the last 12 months.

SMMT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as REGN (100). This means that SMMT’s stock grew similarly to REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REGNSMMT
RSI
ODDS (%)
Bearish Trend 1 day ago
40%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
47%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
62%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
66%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
63%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
61%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 1 day ago
54%
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
45%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RSSB27.400.15
+0.55%
Return Stacked Global Stocks & Bonds ETF
FEAC27.570.13
+0.46%
Fidelity Enhanced U.S. All-Cap Equity ETF
EUSA102.800.09
+0.09%
iShares MSCI USA Equal Weighted ETF
TEMP50.640.01
+0.01%
JPMorgan Climate Change Solutions ETF
ECNS37.49-0.08
-0.21%
iShares MSCI China Small-Cap ETF

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with ROIV. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-1.25%
ROIV - REGN
41%
Loosely correlated
-0.42%
IDYA - REGN
40%
Loosely correlated
-0.28%
ACLX - REGN
39%
Loosely correlated
+0.50%
IOVA - REGN
38%
Loosely correlated
-7.85%
SMMT - REGN
38%
Loosely correlated
-1.55%
More

SMMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SMMT
1D Price
Change %
SMMT100%
-1.55%
BCDA - SMMT
70%
Closely correlated
+1.03%
TIL - SMMT
55%
Loosely correlated
-1.34%
BNTX - SMMT
52%
Loosely correlated
-1.05%
RLAY - SMMT
46%
Loosely correlated
+3.36%
XNCR - SMMT
42%
Loosely correlated
+0.37%
More